Truveris, a pharmacy cost containment and program performance company, raised $15 million in Series E funding led by Canaan Partners and New Leaf Venture Partners. The funding will support corporate development and operational growth. Truveris' platform replaces traditional pharmacy benefit manager models, providing transparency and savings. CEO Nanette Oddo highlighted the validation of their solutions and growth potential. For more information, contact info@truveris.com.

Truveris, a Wilmington, DE-based company which specializes in pharmacy cost containment and program performance, raised $15M in Series E funding.

WILMINGTON, Del.--(BUSINESS WIRE)--Truveris, the leader in pharmacy cost containment and program performance, today announced it has raised $15 million in Series E investment led by two lead investors, Canaan Partners and New Leaf Venture Partners. The funding will support Truveris’ next stage of corporate development and operational growth as it continues to deliver best-in-class pharmacy benefit solutions to employers nationwide. Truveris’ proprietary technology platform replaces traditional PBM (pharmacy benefit manager) contracting and renewal models. It creates a transparent and dynamic competitive marketplace that drives significant savings on pharmacy pricing and improved contract terms. Truveris’ technology also provides ongoing analysis of 100% of claims throughout the life of the contract to ensure contract compliance, enable program optimization, and satisfy fiduciary responsibilities. “We are pleased by the continued commitment of Truveris’ current long-term investors, Caanan and New Leaf, to advancing the company’s success,” said Nanette Oddo, Chief Executive Officer, Truveris